药品上市许可持有人制度对医药产业创新的影响研究

Research on the influence of marketing authorization holder system on pharmaceutical industry innovation

基于2016年药品上市许可持有人(marketing authorization holder, MAH)制度试点这一准自然实验,使用2011—2021年医药制造业省级面板数据,构建双重差分模型实证考察了MAH制度试点政策对医药产业创新的影响及其作用机制。结果表明:无论是从创新投入还是从创新产出的角度,MAH制度的推行都能够显著促进我国医药产业创新发展,这一结论在经过一系列稳健性检验后依然成立。机制分析发现MAH制度试点政策能够通过提升人力资本集聚和研发资本集聚、强化政府支持来实现对医药创新的促进效应。进一步的异质性研究表明MAH试点对知识产权保护水平较高的地区医药创新的激励作用更强。基于此,应着力优化MAH制度的政策环境,发挥要素集聚优势,加大政策引导和政府支持,持续优化医药行业资源配置,从而推动我国医药产业创新发展。

Based on the quasi-natural experiment of marketing authorization holder(MAH)system pilot in 2016,this article employs the provincial panel data of the pharmaceutical manufacturing industry from 2011 to 2021 to construct a difference-in-difference model for analysis.The results show that,no matter from the perspective of innovation input or innovation output,the implementation of MAH system can significantly promote the innovation and development of China's pharmaceutical industry.The conclusion is still valid after a series of robustness tests.Mechanism analysis reveals that the pilot policy of MAH system can achieve the promotion effect on the pharmaceutical innovation by improving the agglomeration of the factors and strengthening the government support.Further research shows that the MAH pilot has a stronger incentive effect on the pharmaceutical innovation in the regions with high protection level of intellectual property.Based on these,government should focus on optimizing the policy environment of the MAH system,give full play to the advantages of factor agglomeration,increase policy guidance and government support,and continuously optimize the allocation of resources in the pharmaceutical industry,so as to promote the innovation and development of China's pharmaceutical industry.